精神分裂症患者的多药耐药基因多态性与利培酮的疗效及不良反应的相关性  

Relationship between MDR1 gene polymorphisms and therapeutic response to risperidone in schizophrenic patients

作　　者：王晓志[1] 宓为峰[1] 邹连勇[1] 卢天兰[1] 李玲芝[1] 张鸿燕[1] 

机构地区：[1]北京大学精神卫生研究所卫生部精神卫生学重点实验室,北京100191

出　　处：《中国临床药理学杂志》2012年第7期496-498,共3页The Chinese Journal of Clinical Pharmacology

摘　　要：目的观察中国汉族精神分裂症患者多药耐药基因多态性与利培酮临床疗效和不良反应的相关性。方法入选192例符合DSM-IV精神分裂症诊断的患者,给予利培酮每天2～6 mg,治疗8周。在治疗基线、第4,8周,用阳性与阴性症状量表(PANSS)评估临床疗效。用聚合酶链式反应(PCR)和限制酶切法,检测患者rs1045642和rs2235048的基因多态性。不良反应观察指标为锥体外系不良反应(EPS)发生率、各实验室检查值的变化。结果 PANSS减分率在rs1045642和rs2235048不同基因型及等位基因间分布差异无统计学意义(P>0.05);药物不良反应和EPS的发生率在各基因型和等位基因间差异无统计学意义(P>0.05)。结论多药耐药基因rs1045642和rs2235048的基因多态性与利培酮的疗效和安全性可能无关联。Objective To investigate the relationship between MDR1 gene polymorphism and clinical response in Chinese schizophrenic patients treated with risperidone.Methods One hundred and ninety two patients affected by schizophrenia were treated with risperidone（2-6 mg·d-1） for 8 weeks.The clinical response was evaluated with PANSS.Adverse drug reactions were evaluated by rate of EPS and level change of other variables.PCR-RFLP was used to detect rs1045642 and rs2235048 gene polymorphism.Results There were no statistical significant differences of main clinical response and adverse drug reactions among different genotypes and allele carriers.Conclusion Non-significant associations were found between the polymorphisms of rs1045642,rs2235048 and treatment response of risperidone.

关 键 词：多药耐药基因 利培酮 多态性 精神分裂症 

分 类 号：R971.41[医药卫生—药品] R749.3[医药卫生—药学]